Japanese automakers sold 4,598,615 new cars in 2020, slumping by 11.5 percent from a year earlier, to mark the largest decline since 2011.
The cars sold includes 1, 718,088 mini-vehicles with engines of up to 660 cc, which as a category also went down 10.1 percent on-year.
Excluding mini-vehicles from the total, sales would have dropped 2.3 percent to 2,880,527 units.
Mitsubishi Motors Corp. posted the worst domestic sales decline in 2020 among Japanese carmakers at 41.3 percent on-year, followed by Nissan Motor Co., which suffered a 27.5 percent fall.
Toyota Motor Corp. dealt with a 5.8 percent drop.
The other automakers include Honda Motor Co. Mazda Motor Corp., Suzuki Motor Corp. and Toyota subsidiary Daihatsu Motor Co.
Car sales picked up after a slump in the spring of 2020 when Japan was under a state of emergency over the novel coronavirus.
Car sales usually increase toward April, when a new business and school calendar begins in the country.
The outlook for Japanese carmakers remains uncertain in 2021 as the government is planning to declare another state of emergency due to the pandemic.


Bill Gates Warns Governments Are Unprepared for AI Disruption
UK Businesses Urge Government to Cut Electricity Levies
Global Central Banks Brace for More Rate Hikes as Inflation Risks Rise
Enflame Shares Surge 200% in Shanghai AI Chip Debut
German 2-Year Yield Hits 2023 High as Rate Hike Bets Rise
Samsung Heavy Wins $1.22 Billion LNG Carrier and Tanker Deal
China Industrial Output Beats Forecasts as Exports Support Growth
Meta’s AI Shopping Push Grows as Agentic Commerce Remains Below 1%
Gold Prices Steady as Oil Disruptions Boost Fed Rate Hike Bets
Volkswagen Job Cuts Put Lower Saxony Leader Under Political Pressure
Samsung, SK Hynix Reject KEPCO’s $18.7 Billion Power Funding Plan
Dollar Rises as Fed Hike Bets Weigh on Asian Currencies
SoftBank Shares Jump 8% as SB Energy IPO Optimism Builds
Anthropic Eyes Second Straight Profitable Quarter Ahead of Potential IPO
Can Europe shake its Russia links for good?
Nvidia Eyes $10 Billion Investment in Anthropic IPO
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 



